Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Key Points

• This research aims to evaluate the effect of adding bevacizumab to a fluorouracil-based chemotherapy regimen on patient survival in metastatic colorectal cancer.
• Analyzed the addition of bevacizumab to fluorouracil-based chemotherapy.
• Included patients diagnosed with metastatic colorectal cancer.
• Measured survival rates as the primary outcome.
• The addition of bevacizumab resulted in a statistically significant improvement in survival compared to chemotherapy alone.